Mechanistically, while MYC inhibition destroyed CSCs, it also augmented the ability of cisplatin to kill non-stem tumor cells in HNSCC by enhancing the DNA damage response, which activated antitumor immunity by recruiting CD8+ T cells through chemokines (Figures 8C). Here, CD8A is linked to head and neck squamous cell carcinoma.